http://www.biocentury.com/rss/weekinreviewWeek in Reviewen-US Copyright 2013 BioCentury, Inc.RSS Generatorhttp://www.biocentury.com/Data/NewsCenter2/Images/WeekInReview/Coverstory.gifhttp://www.biocentury.com/rss/weekinreviewhttp://www.biocentury.com/weekinreview/deals/2013-06-17/abcodia-ait-austrian-institute-of-technology-gmbh-deal-320570http://www.biocentury.com/weekinreview/deals/2013-06-17/abcodia-ait-austrian-institute-of-technology-gmbh-deal-320570DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/algeta-avipep-deal-320571http://www.biocentury.com/weekinreview/deals/2013-06-17/algeta-avipep-deal-320571DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/amgen-cytokinetics-deal-320572http://www.biocentury.com/weekinreview/deals/2013-06-17/amgen-cytokinetics-deal-320572DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/aphios-vivacell-biotechnology-espana-sl-deal-320573http://www.biocentury.com/weekinreview/deals/2013-06-17/aphios-vivacell-biotechnology-espana-sl-deal-320573DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/astrazeneca-cancer-research-uk-university-of-manchester-deal-320574http://www.biocentury.com/weekinreview/deals/2013-06-17/astrazeneca-cancer-research-uk-university-of-manchester-deal-320574DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/biolinerx-jiangsu-chia-tai-tianqing-deal-320575http://www.biocentury.com/weekinreview/deals/2013-06-17/biolinerx-jiangsu-chia-tai-tianqing-deal-320575DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/biological-e-valneva-deal-320577http://www.biocentury.com/weekinreview/deals/2013-06-17/biological-e-valneva-deal-320577DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/biolog-id-institut-curie-deal-320576http://www.biocentury.com/weekinreview/deals/2013-06-17/biolog-id-institut-curie-deal-320576DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/bioniche-paladin-deal-320578http://www.biocentury.com/weekinreview/deals/2013-06-17/bioniche-paladin-deal-320578DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/conceptus-bayer-deal-320579http://www.biocentury.com/weekinreview/deals/2013-06-17/conceptus-bayer-deal-320579DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/crelux-4sc-ucb-deal-320580http://www.biocentury.com/weekinreview/deals/2013-06-17/crelux-4sc-ucb-deal-320580DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/de-shaw-research-llc-zealand-pharma-deal-320581http://www.biocentury.com/weekinreview/deals/2013-06-17/de-shaw-research-llc-zealand-pharma-deal-320581DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/elan-royalty-pharma-deal-320582http://www.biocentury.com/weekinreview/deals/2013-06-17/elan-royalty-pharma-deal-320582DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/flamel-deal-320583http://www.biocentury.com/weekinreview/deals/2013-06-17/flamel-deal-320583DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/genomic-vision-quest-diagnostics-deal-320584http://www.biocentury.com/weekinreview/deals/2013-06-17/genomic-vision-quest-diagnostics-deal-320584DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/immune-design-cri-ludwig-institute-for-cancer-research-deal-320585http://www.biocentury.com/weekinreview/deals/2013-06-17/immune-design-cri-ludwig-institute-for-cancer-research-deal-320585DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/immunogenes-corvinus-venture-capital-fund-manager-deal-320586http://www.biocentury.com/weekinreview/deals/2013-06-17/immunogenes-corvinus-venture-capital-fund-manager-deal-320586DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/isis-pharmaceuticals-xenon-deal-320587http://www.biocentury.com/weekinreview/deals/2013-06-17/isis-pharmaceuticals-xenon-deal-320587DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/isomerase-therapeutics-ltd-neurovive-deal-320588http://www.biocentury.com/weekinreview/deals/2013-06-17/isomerase-therapeutics-ltd-neurovive-deal-320588DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/life-technologies-life-science-korea-(lsk)-deal-320589http://www.biocentury.com/weekinreview/deals/2013-06-17/life-technologies-life-science-korea-(lsk)-deal-320589DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/myriad-genetics-astrazeneca-deal-320590http://www.biocentury.com/weekinreview/deals/2013-06-17/myriad-genetics-astrazeneca-deal-320590DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/neurovive-sihuan-deal-320591http://www.biocentury.com/weekinreview/deals/2013-06-17/neurovive-sihuan-deal-320591DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/oculus-deal-320592http://www.biocentury.com/weekinreview/deals/2013-06-17/oculus-deal-320592DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/pearl-therapeutics-astrazeneca-deal-320593http://www.biocentury.com/weekinreview/deals/2013-06-17/pearl-therapeutics-astrazeneca-deal-320593DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/replicel-shiseido-co-ltd-deal-320594http://www.biocentury.com/weekinreview/deals/2013-06-17/replicel-shiseido-co-ltd-deal-320594DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/santhera-national-institutes-of-health-deal-320595http://www.biocentury.com/weekinreview/deals/2013-06-17/santhera-national-institutes-of-health-deal-320595DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/shionogi-tb-alliance-deal-320596http://www.biocentury.com/weekinreview/deals/2013-06-17/shionogi-tb-alliance-deal-320596DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-06-17/theradiag-unicancer-group-deal-320597http://www.biocentury.com/weekinreview/deals/2013-06-17/theradiag-unicancer-group-deal-320597DealsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/access-pharmaceuticals-amag-pharmaceuticals-sales-and-marketing-update-320665http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/access-pharmaceuticals-amag-pharmaceuticals-sales-and-marketing-update-320665Sales and MarketingMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/ahn-gook-effrx-sales-and-marketing-update-320666http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/ahn-gook-effrx-sales-and-marketing-update-320666Sales and MarketingMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/alliance-pharma-novartis-sales-and-marketing-update-320668http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/alliance-pharma-novartis-sales-and-marketing-update-320668Sales and MarketingMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/almirall-ironwood-sales-and-marketing-update-320667http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/almirall-ironwood-sales-and-marketing-update-320667Sales and MarketingMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/aqua-pharmaceuticals-glaxosmithkline-sales-and-marketing-update-320669http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/aqua-pharmaceuticals-glaxosmithkline-sales-and-marketing-update-320669Sales and MarketingMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/bio-reference-laboratories-sales-and-marketing-update-320670http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/bio-reference-laboratories-sales-and-marketing-update-320670Sales and MarketingMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/dainippon-sumitomo-sales-and-marketing-update-320671http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/dainippon-sumitomo-sales-and-marketing-update-320671Sales and MarketingMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/diaxonhit-xdx-inc-sales-and-marketing-update-320672http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/diaxonhit-xdx-inc-sales-and-marketing-update-320672Sales and MarketingMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/gene-by-gene-ltd-sales-and-marketing-update-320673http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/gene-by-gene-ltd-sales-and-marketing-update-320673Sales and MarketingMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/hologic-quest-diagnostics-sales-and-marketing-update-320674http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/hologic-quest-diagnostics-sales-and-marketing-update-320674Sales and MarketingMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/incelldx-kindstar-global-co-ltd-sales-and-marketing-update-320675http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/incelldx-kindstar-global-co-ltd-sales-and-marketing-update-320675Sales and MarketingMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/oxford-gene-sales-and-marketing-update-320676http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/oxford-gene-sales-and-marketing-update-320676Sales and MarketingMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/pathway-genomics-sales-and-marketing-update-320677http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/pathway-genomics-sales-and-marketing-update-320677Sales and MarketingMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/pfizer-takeda-sales-and-marketing-update-320678http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/pfizer-takeda-sales-and-marketing-update-320678Sales and MarketingMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/questcor-novartis-sales-and-marketing-update-320679http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/questcor-novartis-sales-and-marketing-update-320679Sales and MarketingMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/quinnova-suneva-sales-and-marketing-update-320680http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/quinnova-suneva-sales-and-marketing-update-320680Sales and MarketingMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/renaissance-acquisition-holdings-llc-glaxosmithkline-sales-and-marketing-update-320681http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/renaissance-acquisition-holdings-llc-glaxosmithkline-sales-and-marketing-update-320681Sales and MarketingMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/zeria-astellas-sales-and-marketing-update-320682http://www.biocentury.com/weekinreview/salesmarketing/2013-06-17/zeria-astellas-sales-and-marketing-update-320682Sales and MarketingMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-06-17/23andme-management-update-320487http://www.biocentury.com/weekinreview/management/2013-06-17/23andme-management-update-320487ManagementMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-06-17/affymax-management-update-320477http://www.biocentury.com/weekinreview/management/2013-06-17/affymax-management-update-320477ManagementMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-06-17/allenex-management-update-320478http://www.biocentury.com/weekinreview/management/2013-06-17/allenex-management-update-320478ManagementMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-06-17/anthera-management-update-320479http://www.biocentury.com/weekinreview/management/2013-06-17/anthera-management-update-320479ManagementMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-06-17/cubist-management-update-320480http://www.biocentury.com/weekinreview/management/2013-06-17/cubist-management-update-320480ManagementMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-06-17/dezima-management-update-320481http://www.biocentury.com/weekinreview/management/2013-06-17/dezima-management-update-320481ManagementMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-06-17/graybug-management-update-320482http://www.biocentury.com/weekinreview/management/2013-06-17/graybug-management-update-320482ManagementMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-06-17/histogenics-management-update-320483http://www.biocentury.com/weekinreview/management/2013-06-17/histogenics-management-update-320483ManagementMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-06-17/miragen-management-update-320484http://www.biocentury.com/weekinreview/management/2013-06-17/miragen-management-update-320484ManagementMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-06-17/stemcells-management-update-320485http://www.biocentury.com/weekinreview/management/2013-06-17/stemcells-management-update-320485ManagementMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-06-17/summit-management-update-320486http://www.biocentury.com/weekinreview/management/2013-06-17/summit-management-update-320486ManagementMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/allon-neurology-news-320683http://www.biocentury.com/weekinreview/othercompany/2013-06-17/allon-neurology-news-320683Other NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/amneal-pharmaceuticals-hanmi-pharmaceutical-astrazeneca-generics-gastrointestinal-news-320684http://www.biocentury.com/weekinreview/othercompany/2013-06-17/amneal-pharmaceuticals-hanmi-pharmaceutical-astrazeneca-generics-gastrointestinal-news-320684Other NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/boehringer-ingelheim-biomanufacturing-news-320685http://www.biocentury.com/weekinreview/othercompany/2013-06-17/boehringer-ingelheim-biomanufacturing-news-320685Other NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/bristol-myers-pharmaceuticals-news-320686http://www.biocentury.com/weekinreview/othercompany/2013-06-17/bristol-myers-pharmaceuticals-news-320686Other NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/cornerstone-therapeutics-exela-pharmsci-inc-cardiovascular-news-320687http://www.biocentury.com/weekinreview/othercompany/2013-06-17/cornerstone-therapeutics-exela-pharmsci-inc-cardiovascular-news-320687Other NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/dana-farber-cancer-institute-the-leukemia-and-lymphoma-society-(lls)-cancer-news-320688http://www.biocentury.com/weekinreview/othercompany/2013-06-17/dana-farber-cancer-institute-the-leukemia-and-lymphoma-society-(lls)-cancer-news-320688Other NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/duke-university-national-institutes-of-health-infectious-news-320689http://www.biocentury.com/weekinreview/othercompany/2013-06-17/duke-university-national-institutes-of-health-infectious-news-320689Other NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/florida-legislature-oregon-state-legislature-biosimilars-news-320690http://www.biocentury.com/weekinreview/othercompany/2013-06-17/florida-legislature-oregon-state-legislature-biosimilars-news-320690Other NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/forest-laboratories-pharmaceuticals-news-320691http://www.biocentury.com/weekinreview/othercompany/2013-06-17/forest-laboratories-pharmaceuticals-news-320691Other NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/genentech-pdl-biopharma-roche-cancer-news-320692http://www.biocentury.com/weekinreview/othercompany/2013-06-17/genentech-pdl-biopharma-roche-cancer-news-320692Other NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/gilead-roche-infectious-news-320693http://www.biocentury.com/weekinreview/othercompany/2013-06-17/gilead-roche-infectious-news-320693Other NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/glaxosmithkline-autoimmune-news-320694http://www.biocentury.com/weekinreview/othercompany/2013-06-17/glaxosmithkline-autoimmune-news-320694Other NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/intermune-pulmonary-news-320695http://www.biocentury.com/weekinreview/othercompany/2013-06-17/intermune-pulmonary-news-320695Other NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/maxygen-hematology-other-news-320696http://www.biocentury.com/weekinreview/othercompany/2013-06-17/maxygen-hematology-other-news-320696Other NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/med-biogene-diagnostic-news-320697http://www.biocentury.com/weekinreview/othercompany/2013-06-17/med-biogene-diagnostic-news-320697Other NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/myriad-genetics-american-civil-liberties-union-(aclu)-diagnostic-news-320698http://www.biocentury.com/weekinreview/othercompany/2013-06-17/myriad-genetics-american-civil-liberties-union-(aclu)-diagnostic-news-320698Other NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/neumedicines-us-department-of-health-and-human-services-(hhs)-other-news-320700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/neumedicines-us-department-of-health-and-human-services-(hhs)-other-news-320700Other NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/novamedica-s-fyodorov-eye-microsurgery-complex-federal-state-institution-ophthalmic-news-320699http://www.biocentury.com/weekinreview/othercompany/2013-06-17/novamedica-s-fyodorov-eye-microsurgery-complex-federal-state-institution-ophthalmic-news-320699Other NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/proteostasis-the-michael-j-fox-foundation-for-parkinsons-research-(mjff)-neurology-news-320701http://www.biocentury.com/weekinreview/othercompany/2013-06-17/proteostasis-the-michael-j-fox-foundation-for-parkinsons-research-(mjff)-neurology-news-320701Other NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/sun-pharmaceutical-teva-pfizer-takeda-gastrointestinal-news-320702http://www.biocentury.com/weekinreview/othercompany/2013-06-17/sun-pharmaceutical-teva-pfizer-takeda-gastrointestinal-news-320702Other NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-06-17/teva-genitourinary-news-320703http://www.biocentury.com/weekinreview/othercompany/2013-06-17/teva-genitourinary-news-320703Other NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-06-17/affymax-board-of-directors-update-320473http://www.biocentury.com/weekinreview/management/2013-06-17/affymax-board-of-directors-update-320473Boards of DirectorsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-06-17/autifony-board-of-directors-update-320474http://www.biocentury.com/weekinreview/management/2013-06-17/autifony-board-of-directors-update-320474Boards of DirectorsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-06-17/polyphor-board-of-directors-update-320475http://www.biocentury.com/weekinreview/management/2013-06-17/polyphor-board-of-directors-update-320475Boards of DirectorsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-06-17/regulus-board-of-directors-update-320476http://www.biocentury.com/weekinreview/management/2013-06-17/regulus-board-of-directors-update-320476Boards of DirectorsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/abilify-aripiprazole-regulatory-update-320509http://www.biocentury.com/weekinreview/regulatory/2013-06-17/abilify-aripiprazole-regulatory-update-320509RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/acetadote-acetylcysteine-regulatory-update-320498http://www.biocentury.com/weekinreview/regulatory/2013-06-17/acetadote-acetylcysteine-regulatory-update-320498RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/aridol-mannitol-bronchial-challenge-test-kit-regulatory-update-320510http://www.biocentury.com/weekinreview/regulatory/2013-06-17/aridol-mannitol-bronchial-challenge-test-kit-regulatory-update-320510RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/belviq-lorcaserin-regulatory-update-320492http://www.biocentury.com/weekinreview/regulatory/2013-06-17/belviq-lorcaserin-regulatory-update-320492RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/cimzia-certolizumab-pegol-regulatory-update-320507http://www.biocentury.com/weekinreview/regulatory/2013-06-17/cimzia-certolizumab-pegol-regulatory-update-320507RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/cologuard-stool-dna-colorectal-cancer-screening-assay-regulatory-update-320502http://www.biocentury.com/weekinreview/regulatory/2013-06-17/cologuard-stool-dna-colorectal-cancer-screening-assay-regulatory-update-320502RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/diane-35-cyproteroneethinylestradiol-regulatory-update-320494http://www.biocentury.com/weekinreview/regulatory/2013-06-17/diane-35-cyproteroneethinylestradiol-regulatory-update-320494RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/e-keppra-levetiracetam-regulatory-update-320515http://www.biocentury.com/weekinreview/regulatory/2013-06-17/e-keppra-levetiracetam-regulatory-update-320515RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/filmarray-blood-culture-identification-regulatory-update-320495http://www.biocentury.com/weekinreview/regulatory/2013-06-17/filmarray-blood-culture-identification-regulatory-update-320495RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/heplisav-regulatory-update-320500http://www.biocentury.com/weekinreview/regulatory/2013-06-17/heplisav-regulatory-update-320500RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/humira-adalimumab-regulatory-update-320488http://www.biocentury.com/weekinreview/regulatory/2013-06-17/humira-adalimumab-regulatory-update-320488RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/iluvien-regulatory-update-320489http://www.biocentury.com/weekinreview/regulatory/2013-06-17/iluvien-regulatory-update-320489RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/incivo-regulatory-update-320517http://www.biocentury.com/weekinreview/regulatory/2013-06-17/incivo-regulatory-update-320517RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/jetrea-ocriplasmin-regulatory-update-320514http://www.biocentury.com/weekinreview/regulatory/2013-06-17/jetrea-ocriplasmin-regulatory-update-320514RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/lantus-insulin-glargine-regulatory-update-320512http://www.biocentury.com/weekinreview/regulatory/2013-06-17/lantus-insulin-glargine-regulatory-update-320512RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/lucentis-ranibizumab-regulatory-update-320504http://www.biocentury.com/weekinreview/regulatory/2013-06-17/lucentis-ranibizumab-regulatory-update-320504RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/qsymia-regulatory-update-320518http://www.biocentury.com/weekinreview/regulatory/2013-06-17/qsymia-regulatory-update-320518RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/relistor-methylnaltrexone-regulatory-update-320511http://www.biocentury.com/weekinreview/regulatory/2013-06-17/relistor-methylnaltrexone-regulatory-update-320511RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/revlimid-lenalidomide-regulatory-update-320496http://www.biocentury.com/weekinreview/regulatory/2013-06-17/revlimid-lenalidomide-regulatory-update-320496RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/revolade-eltrombopag-regulatory-update-320506http://www.biocentury.com/weekinreview/regulatory/2013-06-17/revolade-eltrombopag-regulatory-update-320506RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/roactemra-tocilizumab-regulatory-update-320503http://www.biocentury.com/weekinreview/regulatory/2013-06-17/roactemra-tocilizumab-regulatory-update-320503RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/sl-401-regulatory-update-320513http://www.biocentury.com/weekinreview/regulatory/2013-06-17/sl-401-regulatory-update-320513RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/surfaxin-lucinactant-regulatory-update-320499http://www.biocentury.com/weekinreview/regulatory/2013-06-17/surfaxin-lucinactant-regulatory-update-320499RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/teprotumumab-regulatory-update-320505http://www.biocentury.com/weekinreview/regulatory/2013-06-17/teprotumumab-regulatory-update-320505RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/tivopath-tivozanib-regulatory-update-320493http://www.biocentury.com/weekinreview/regulatory/2013-06-17/tivopath-tivozanib-regulatory-update-320493RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/tolvaptan-regulatory-update-320508http://www.biocentury.com/weekinreview/regulatory/2013-06-17/tolvaptan-regulatory-update-320508RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/veregen-sinecatechins-regulatory-update-320501http://www.biocentury.com/weekinreview/regulatory/2013-06-17/veregen-sinecatechins-regulatory-update-320501RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/vitaros-alprostadil-regulatory-update-320491http://www.biocentury.com/weekinreview/regulatory/2013-06-17/vitaros-alprostadil-regulatory-update-320491RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/vs-6063-regulatory-update-320516http://www.biocentury.com/weekinreview/regulatory/2013-06-17/vs-6063-regulatory-update-320516RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/xgeva-denosumab-regulatory-update-320490http://www.biocentury.com/weekinreview/regulatory/2013-06-17/xgeva-denosumab-regulatory-update-320490RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-06-17/zelboraf-vemurafenib-regulatory-update-320497http://www.biocentury.com/weekinreview/regulatory/2013-06-17/zelboraf-vemurafenib-regulatory-update-320497RegulatoryMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/adx-n05-phase-iia-data-320520http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/adx-n05-phase-iia-data-320520Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/aldoxorubicin-preliminary-phase-ib-data-320541http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/aldoxorubicin-preliminary-phase-ib-data-320541Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/aldoxorubicin-preliminary-phase-ib-data-320542http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/aldoxorubicin-preliminary-phase-ib-data-320542Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/apremilast-additional-phase-ii-data-320534http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/apremilast-additional-phase-ii-data-320534Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/apremilast-additional-phase-iii-data-320532http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/apremilast-additional-phase-iii-data-320532Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/apremilast-additional-phase-iii-data-320533http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/apremilast-additional-phase-iii-data-320533Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/avastin-bevacizumab-additional-phase-iii-data-320548http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/avastin-bevacizumab-additional-phase-iii-data-320548Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/belinostat-phase-i-data-320567http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/belinostat-phase-i-data-320567Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/belinostat-phase-i-data-320568http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/belinostat-phase-i-data-320568Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/bmn-673-preliminary-phase-iii-data-320525http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/bmn-673-preliminary-phase-iii-data-320525Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/bnc105-additional-phase-iii-data-320526http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/bnc105-additional-phase-iii-data-320526Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/brodalumab-phase-ii-data-320521http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/brodalumab-phase-ii-data-320521Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/brostallicin-final-phase-ii-data-320537http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/brostallicin-final-phase-ii-data-320537Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/crolibulin-phase-i-data-320547http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/crolibulin-phase-i-data-320547Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/ct-p13-phase-i-data-320538http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/ct-p13-phase-i-data-320538Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/cv-301-phase-ii-data-320524http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/cv-301-phase-ii-data-320524Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/dcp-001-phase-iii-data-320543http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/dcp-001-phase-iii-data-320543Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/decisiondx-melanoma-test-data-320531http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/decisiondx-melanoma-test-data-320531Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/deleobuvir-additional-phase-iib-data-320527http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/deleobuvir-additional-phase-iib-data-320527Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/dn24-02-preliminary-phase-ii-data-320544http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/dn24-02-preliminary-phase-ii-data-320544Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/enbrel-etanercept-data-320522http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/enbrel-etanercept-data-320522Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/epratuzumab-rap-interim-phase-iii-data-320551http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/epratuzumab-rap-interim-phase-iii-data-320551Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/escitalopram-data-320546http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/escitalopram-data-320546Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/faldaprevir-additional-phase-iib-data-320528http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/faldaprevir-additional-phase-iib-data-320528Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/indoximod-phase-i-data-320559http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/indoximod-phase-i-data-320559Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/indoximod-phase-ibii-data-320558http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/indoximod-phase-ibii-data-320558Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/ins001-phase-ib-data-320553http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/ins001-phase-ib-data-320553Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/laquinimod-phase-iia-data-320519http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/laquinimod-phase-iia-data-320519Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/ly2886721-phase-ii-discontinued-320545http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/ly2886721-phase-ii-discontinued-320545Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/mage-a3-antigen-specific-cancer-immunotherapeutic-additional-phase-ii-data-320549http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/mage-a3-antigen-specific-cancer-immunotherapeutic-additional-phase-ii-data-320549Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/mage-a3-antigen-specific-cancer-immunotherapeutic-additional-phase-ii-data-320550http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/mage-a3-antigen-specific-cancer-immunotherapeutic-additional-phase-ii-data-320550Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/margetuximab-phase-i-data-320556http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/margetuximab-phase-i-data-320556Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/miv-711-phase-ia-data-320557http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/miv-711-phase-ia-data-320557Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/nivolumab-interim-phase-ib-data-320562http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/nivolumab-interim-phase-ib-data-320562Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/oral-rigosertib-additional-phase-ii-data-320561http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/oral-rigosertib-additional-phase-ii-data-320561Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/pf-05280014-phase-i-data-320563http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/pf-05280014-phase-i-data-320563Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/pomalyst-pomalidomide-updated-phase-iii-data-320535http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/pomalyst-pomalidomide-updated-phase-iii-data-320535Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/pri-724-phase-i-data-320564http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/pri-724-phase-i-data-320564Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/psma-adc-phase-i-data-320565http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/psma-adc-phase-i-data-320565Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/revlimid-lenalidomide-phase-iii-data-320536http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/revlimid-lenalidomide-phase-iii-data-320536Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/rq-00000010-phase-i-data-320540http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/rq-00000010-phase-i-data-320540Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/rxi-109-phase-i-data-320566http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/rxi-109-phase-i-data-320566Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/sb204-phase-i-data-320560http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/sb204-phase-i-data-320560Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/selinexor-phase-i-data-320554http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/selinexor-phase-i-data-320554Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/trebananib-phase-iii-data-320523http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/trebananib-phase-iii-data-320523Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/ublituximab-phase-i-data-320555http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/ublituximab-phase-i-data-320555Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/veltuzumab-rap-interim-phase-iii-data-320552http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/veltuzumab-rap-interim-phase-iii-data-320552Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/vtx-2337-phase-ib-data-320569http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/vtx-2337-phase-ib-data-320569Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/yervoy-ipilimumab-phase-i-data-320530http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/yervoy-ipilimumab-phase-i-data-320530Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/yervoy-ipilimumab-phase-ib-data-320529http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/yervoy-ipilimumab-phase-ib-data-320529Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/zelboraf-vemurafenib-phase-i-data-320539http://www.biocentury.com/weekinreview/clinicalresults/2013-06-17/zelboraf-vemurafenib-phase-i-data-320539Clinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/preclinical/2013-06-17/genoa-pharmaceuticals-preclinical-data-320598http://www.biocentury.com/weekinreview/preclinical/2013-06-17/genoa-pharmaceuticals-preclinical-data-320598Preclinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/preclinical/2013-06-17/rhizen-preclinical-data-320599http://www.biocentury.com/weekinreview/preclinical/2013-06-17/rhizen-preclinical-data-320599Preclinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/preclinical/2013-06-17/tetraphase-preclinical-data-320600http://www.biocentury.com/weekinreview/preclinical/2013-06-17/tetraphase-preclinical-data-320600Preclinical ResultsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/adcetris-brentuximab-vedotin-phase-iii-started-320629http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/adcetris-brentuximab-vedotin-phase-iii-started-320629Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/agenmestencel-t-phase-iii-start-320602http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/agenmestencel-t-phase-iii-start-320602Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/atrasentan-phase-iii-started-320601http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/atrasentan-phase-iii-started-320601Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/aut00063-phase-i-started-320605http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/aut00063-phase-i-started-320605Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/bmn-165-phase-iii-started-320607http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/bmn-165-phase-iii-started-320607Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/c-cure-phase-iii-started-320609http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/c-cure-phase-iii-started-320609Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/ctp-354-phase-i-started-320612http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/ctp-354-phase-i-started-320612Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/dcvax-direct-phase-iii-started-320619http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/dcvax-direct-phase-iii-started-320619Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/debio-1143-phase-i-started-320604http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/debio-1143-phase-i-started-320604Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/gsk2618960-phase-i-halted-320614http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/gsk2618960-phase-i-halted-320614Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/h5n1-vlp-vaccine-phase-ii-started-320617http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/h5n1-vlp-vaccine-phase-ii-started-320617Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/hgh-ctp-phase-iii-started-320625http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/hgh-ctp-phase-iii-started-320625Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/hqk-1001-completed-phase-iib-enrollment-320615http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/hqk-1001-completed-phase-iib-enrollment-320615Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/ict-107-phase-ii-ongoing-320616http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/ict-107-phase-ii-ongoing-320616Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/inavir-laninamivir-octanoate-phase-ii-started-320608http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/inavir-laninamivir-octanoate-phase-ii-started-320608Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/intercept-blood-system-for-red-blood-cells-phase-iii-started-320610http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/intercept-blood-system-for-red-blood-cells-phase-iii-started-320610Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/intercept-blood-system-for-red-blood-cells-phase-iii-started-320611http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/intercept-blood-system-for-red-blood-cells-phase-iii-started-320611Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/lipicell-completed-phase-i-enrollment-320606http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/lipicell-completed-phase-i-enrollment-320606Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/moxy-drug-coated-balloon-phase-iii-started-320613http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/moxy-drug-coated-balloon-phase-iii-started-320613Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/nrx-1074-phase-i-started-320618http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/nrx-1074-phase-i-started-320618Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/oms721-phase-i-start-320621http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/oms721-phase-i-start-320621Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/oral-neratinib-phase-iii-started-320626http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/oral-neratinib-phase-iii-started-320626Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/otx-dp-completed-phase-ii-enrollment-320620http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/otx-dp-completed-phase-ii-enrollment-320620Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/pe0139-phase-i-started-320624http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/pe0139-phase-i-started-320624Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/ponatinib-phase-ii-started-320603http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/ponatinib-phase-ii-started-320603Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/pt003-phase-iii-start-320623http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/pt003-phase-iii-start-320623Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/pt003-phase-iii-started-320622http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/pt003-phase-iii-started-320622Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/rhb-104-phase-iia-started-320628http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/rhb-104-phase-iia-started-320628Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/rpc1063-spa-received-320627http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/rpc1063-spa-received-320627Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/ti-001-phase-ii-started-320630http://www.biocentury.com/weekinreview/clinicalstatus/2013-06-17/ti-001-phase-ii-started-320630Clinical StatusMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-ab-science-completes-convertible-bond-financing-320631http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-ab-science-completes-convertible-bond-financing-320631Completed OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-actinium-completes-warrant-exercise-320632http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-actinium-completes-warrant-exercise-320632Completed OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-anacor-completes-debt-financing-320633http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-anacor-completes-debt-financing-320633Completed OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-bioporto-diagnostics-completes-debt-financing-320634http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-bioporto-diagnostics-completes-debt-financing-320634Completed OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-cempra-completes-follow-on-320635http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-cempra-completes-follow-on-320635Completed OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-clovis-completes-follow-on-320636http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-clovis-completes-follow-on-320636Completed OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-dermira-completes-venture-financing-320637http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-dermira-completes-venture-financing-320637Completed OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-diagnoplex-completes-venture-financing-320638http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-diagnoplex-completes-venture-financing-320638Completed OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-enzo-completes-debt-financing-320639http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-enzo-completes-debt-financing-320639Completed OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-invion-completes-private-placement-320640http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-invion-completes-private-placement-320640Completed OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-lam-therapeutics-completes-venture-financing-320641http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-lam-therapeutics-completes-venture-financing-320641Completed OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-mast-therapeutics-completes-follow-on-320642http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-mast-therapeutics-completes-follow-on-320642Completed OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-prism-pharma-completes-venture-financing-320643http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-prism-pharma-completes-venture-financing-320643Completed OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-retroscreen-virology-completes-placing-320644http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-retroscreen-virology-completes-placing-320644Completed OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-valeritas-completes-venture-financing-320645http://www.biocentury.com/weekinreview/offerings/2013-06-17/completedofferings-valeritas-completes-venture-financing-320645Completed OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/proposedofferings-agios-proposes-ipo-320646http://www.biocentury.com/weekinreview/offerings/2013-06-17/proposedofferings-agios-proposes-ipo-320646Proposed OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/proposedofferings-conatus-proposes-ipo-320647http://www.biocentury.com/weekinreview/offerings/2013-06-17/proposedofferings-conatus-proposes-ipo-320647Proposed OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/proposedofferings-intercept-pharmaceuticals-proposes-follow-on-320648http://www.biocentury.com/weekinreview/offerings/2013-06-17/proposedofferings-intercept-pharmaceuticals-proposes-follow-on-320648Proposed OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/proposedofferings-valneva-proposes-rights-offering-320649http://www.biocentury.com/weekinreview/offerings/2013-06-17/proposedofferings-valneva-proposes-rights-offering-320649Proposed OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/amendedofferings-esperion-amends-ipo-320650http://www.biocentury.com/weekinreview/offerings/2013-06-17/amendedofferings-esperion-amends-ipo-320650Amended OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/amendedofferings-nanostring-amends-ipo-320651http://www.biocentury.com/weekinreview/offerings/2013-06-17/amendedofferings-nanostring-amends-ipo-320651Amended OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/amendedofferings-reprocell-amends-ipo-320652http://www.biocentury.com/weekinreview/offerings/2013-06-17/amendedofferings-reprocell-amends-ipo-320652Amended OfferingsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-affymax-financial-update-320653http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-affymax-financial-update-320653Other Financial NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-autifony-financial-update-320654http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-autifony-financial-update-320654Other Financial NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-celgene-financial-update-320655http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-celgene-financial-update-320655Other Financial NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-echo-therapeutics-financial-update-320656http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-echo-therapeutics-financial-update-320656Other Financial NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-genmab-financial-update-320657http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-genmab-financial-update-320657Other Financial NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-mela-sciences-financial-update-320658http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-mela-sciences-financial-update-320658Other Financial NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-nasdaq-omx-group-inc-financial-update-320659http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-nasdaq-omx-group-inc-financial-update-320659Other Financial NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-ocular-therapeutix-financial-update-320660http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-ocular-therapeutix-financial-update-320660Other Financial NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-ohr-financial-update-320661http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-ohr-financial-update-320661Other Financial NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-pdl-biopharma-financial-update-320662http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-pdl-biopharma-financial-update-320662Other Financial NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-valeant-pharmaceuticals-financial-update-320663http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-valeant-pharmaceuticals-financial-update-320663Other Financial NewsMon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-valirx-financial-update-320664http://www.biocentury.com/weekinreview/offerings/2013-06-17/otherfinancialnews-valirx-financial-update-320664Other Financial NewsMon, 17 Jun 2013 00:00:00 -0700